BofA Trims Target as Pipeline Catalysts Stay in Focus
AbbVie Inc. (NYSE: ABBV) is trading lower on Tuesday, December 16, 2025, after a strong run earlier in the quarter and a Monday close that kept the stock near the upper end of its 52‑week range. As of 17:54 UTC on Dec. 16, ABBV was at $222.44, down $5.01 (-2.20%) on the session, with an intraday range of $222.44 to $228.00.
Today’s AbbVie coverage is being driven less by a single blockbuster headline and more by the familiar mix of Wall Street recalibration and pipeline expectations: Bank of America trimmed its price target, while fresh pipeline-focused analysis reiterated the thesis that AbbVie’s next wave of launches and label expansions—especially around Rinvoq—could power the company’s post‑Humira growth story through…
